세계의 AI 종양 진화 맵 시장 예측(-2032년) : 암 유형별, 기술별, 용도별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global AI Tumor Evolution Maps Market is accounted for $196.03 million in 2025 and is expected to reach $1390.77 million by 2032 growing at a CAGR of 32.3% during the forecast period. Artificial Intelligence Tumor Evolution Maps are innovative systems designed to study how cancers develop, mutate, and react to different therapies over time. These maps process extensive genomic profiles, medical scans, and patient records to uncover the dynamic nature of tumor progression. By revealing how cancer cells adapt and acquire drug resistance, they assist researchers in forecasting clinical outcomes and tailoring personalized treatments. Unlike conventional approaches, AI-driven models merge diverse datasets, highlighting subtle interactions within tumor biology that might otherwise remain hidden. This cutting-edge methodology equips oncologists with deeper insights, enabling more accurate therapeutic decisions and offering improved prospects for cancer management.

According to the International Agency for Research on Cancer (IARC), The number of cancer-associated deaths is projected to increase from 7.6 million in 2008 to 13 million in 2030-a rise of approximately 72%.

Market Dynamics:

Driver:

Increasing cancer incidence

The global rise in cancer cases is significantly boosting the demand for AI Tumor Evolution Maps. With more patients being diagnosed, healthcare systems require sophisticated tools to track tumor growth, anticipate changes, and support individualized therapy decisions. AI-based maps allow clinicians to process extensive genomic and clinical datasets, enhancing care management. Increasing awareness of cancer risks and treatment options, along with the growth of various cancer types, further stimulates the adoption of these technologies. This situation drives investment in AI solutions that aid in early detection, precise treatment strategies, and improved patient survival, making them an essential part of modern oncology practices.

Restraint:

High implementation costs

The significant cost of implementing AI Tumor Evolution Maps is a major market restraint. Establishing and maintaining these systems requires heavy investment in computing hardware, software solutions, and skilled professionals. Smaller healthcare facilities often cannot bear these costs, limiting their access to AI-powered tumor mapping. Additional expenses related to software updates, data management, and integration with existing clinical workflows further compound the challenge. These financial barriers can slow market growth, restrict the entry of new competitors, and hinder adoption in developing regions. Despite the advantages of AI-driven tumor evolution tools, high implementation costs remain a critical factor preventing broader utilization across hospitals and clinics worldwide.

Opportunity:

Increasing demand for precision oncology

Rising interest in precision oncology offers strong growth potential for the AI Tumor Evolution Maps market. Both patients and healthcare providers are increasingly focused on personalized treatment approaches that consider individual tumor characteristics, genetic alterations, and therapy outcomes. AI-enabled tumor evolution platforms can analyze complex information, detect subtle patterns, and generate actionable recommendations for customized treatments. As precision medicine gains traction, the need for AI tools that support accurate prognosis, optimize therapy, and anticipate resistance is growing. Providers of AI-based tumor mapping solutions can capitalize on this demand to expand their market reach, improve patient care, and advance the implementation of targeted cancer therapies globally.

Threat:

Competition from traditional methods

Traditional cancer diagnostic and monitoring techniques present a threat to the AI Tumor Evolution Maps market. Traditional approaches such as biopsies, pathology examinations, and standard imaging techniques are well-established, reliable, and generally more affordable compared to AI-driven platforms. Healthcare providers may hesitate to implement new AI technologies due to concerns over accuracy, workflow integration, and training requirements. Resistance to adopting novel approaches can slow the market penetration of AI tumor evolution solutions, especially in resource-limited regions. Traditional methods also benefit from regulatory approval experience and extensive clinical validation. As a result, AI platforms face strong competition from conventional practices, which may limit adoption despite the potential for technological improvements.

Covid-19 Impact:

The COVID-19 pandemic had a notable effect on the AI Tumor Evolution Maps market. Many hospitals and research centers experienced disruptions in routine cancer care, including screenings, therapies, and clinical studies, leading to a temporary decline in demand for AI-based tumor mapping systems. Supply chain delays further hindered the deployment of necessary hardware and software. Conversely, the pandemic accelerated the integration of digital health solutions, telemedicine, and AI analytics, demonstrating the critical role of remote monitoring and predictive healthcare tools. Consequently, although short-term market growth slowed, COVID-19 underscored the importance of AI tumor evolution platforms in improving patient management, enhancing decision-making, and strengthening healthcare resilience.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is expected to account for the largest market share during the forecast period. This dominance is due to the high prevalence of breast cancer worldwide and significant investments in AI research aimed at improving breast cancer care. AI-driven tools, including deep learning models and sophisticated imaging technologies, have significantly improved early detection, tailored treatment strategies, and ongoing monitoring of tumor development in breast cancer patients. As AI technologies continue to evolve, their application in breast cancer is expected to expand, reinforcing its leading role in the AI tumor mapping market.

The AI & health tech startups segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the AI & health tech startups segment is predicted to witness the highest growth rate. This growth is fueled by innovations in personalized medicine, where AI customizes treatments based on individual genetic information, lifestyle, and health history. Moreover, these startups are pioneering the integration of AI with genomics and clinical data, providing novel solutions that significantly improve the precision and effectiveness of cancer diagnostics and treatment strategies. Their adaptability and emphasis on advanced technologies establish them as key players in the rapidly advancing field of AI-powered oncology.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. This leadership is driven by factors such as cutting-edge healthcare facilities, significant R&D investments, and a high incidence of cancer. Government support, including favorable regulations and initiatives, has further accelerated the adoption of AI technologies in oncology. The concentration of prominent technology firms and prestigious medical institutions in the region has created a robust ecosystem for the advancement and implementation of AI-based cancer diagnostic and treatment solutions.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. This surge is attributed to factors such as a rising prevalence of cancer, improvements in healthcare infrastructure, and an increased adoption of artificial intelligence in medical diagnostics. Nations like China, Japan, and India are making substantial investments in AI research and development, creating a favorable environment for market growth. Furthermore, partnerships between healthcare institutions and technology companies are facilitating the integration of AI solutions in oncology. These factors collectively position the APAC region as a key player in the global AI Tumor Evolution Maps market.

Key players in the market

Some of the key players in AI Tumor Evolution Maps Market include Azra AI, Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Median Technologies, PathAI, Paige, AstraZeneca, CancerIQ, X-ZELL, MNM Bioscience, Biotome, Immunai, OncoHost, Tempus and 1Cell.Ai.

Key Developments:

In August 2025, GE HealthCare and Gentuity LLC plan to collaborate on commercial activities to enhance the availability, adoption and functionality of highly complementary imaging solutions for interventional cardiology. The collaboration is intended to enhance the availability, adoption and functionality of highly complementary imaging solutions for interventional cardiology.

In April 2025, Azra AI and Elekta announce partnership to enhance cancer registry operations with AI-powered automation. This partnership combines Azra AI's real-time patient identification and workflow automation with Elekta's next-generation cancer registry software, Elekta ONE Registry Informatics*. The combined technologies will enable cancer registry teams to automate cancer casefinding, streamline data ingestion, increase reporting accuracy, and ensure compliance with national and international standards.

In January 2025, Siemens Healthineers has entered into a technology licensing agreement with Kromek Group Plc to enable the in-house production of cadmium zinc telluride (CZT) material for gamma ray detectors used in single-photon emission computed tomography (SPECT) systems. Under the terms of the agreement, Siemens Healthineers will license Kromek's technology to produce CZT, which will extend its research, development, and manufacturing capabilities to allow for a potential future line of gamma ray detectors for multi-modal SPECT systems.

Cancer Types Covered:

• Brain Cancer
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Pancreatic Cancer
• Hematologic Malignancies
• Rare & Pediatric Cancers
• Other Cancer Types

Technologies Covered:

• Imaging-Based Mapping (MRI, CT, PET)
• Genomic and Transcriptomic Mapping
• AI-Powered Predictive Modeling
• Multi-Omics Integration Platforms
• Spatial Transcriptomics
• Digital Twin Modeling
• Federated Learning & Privacy-Preserving AI

Applications Covered:

• Diagnosis and Early Detection
• Prognosis and Risk Assessment
• Treatment Planning
• Drug Development and Clinical Trials
• Tumor Monitoring and Recurrence Prediction
• Biomarker Discovery
• Patient Stratification for Immunotherapy

End Users Covered:

• Hospitals and Clinics
• Research Institutes
• Pharmaceutical & Biotechnology Companies
• Academic Institutions
• Diagnostic Laboratories
• AI & Health Tech Startups

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global AI Tumor Evolution Maps Market, By Cancer Type

• 5.1 Introduction
• 5.2 Brain Cancer
• 5.3 Lung Cancer
• 5.4 Breast Cancer
• 5.5 Colorectal Cancer
• 5.6 Prostate Cancer
• 5.7 Pancreatic Cancer
• 5.8 Hematologic Malignancies
• 5.9 Rare & Pediatric Cancers
• 5.10 Other Cancer Types

6 Global AI Tumor Evolution Maps Market, By Technology

• 6.1 Introduction
• 6.2 Imaging-Based Mapping (MRI, CT, PET)
• 6.3 Genomic and Transcriptomic Mapping
• 6.4 AI-Powered Predictive Modeling
• 6.5 Multi-Omics Integration Platforms
• 6.6 Spatial Transcriptomics
• 6.7 Digital Twin Modeling
• 6.8 Federated Learning & Privacy-Preserving AI

7 Global AI Tumor Evolution Maps Market, By Application

• 7.1 Introduction
• 7.2 Diagnosis and Early Detection
• 7.3 Prognosis and Risk Assessment
• 7.4 Treatment Planning
• 7.5 Drug Development and Clinical Trials
• 7.6 Tumor Monitoring and Recurrence Prediction
• 7.7 Biomarker Discovery
• 7.8 Patient Stratification for Immunotherapy

8 Global AI Tumor Evolution Maps Market, By End User

• 8.1 Introduction
• 8.2 Hospitals and Clinics
• 8.3 Research Institutes
• 8.4 Pharmaceutical & Biotechnology Companies
• 8.5 Academic Institutions
• 8.6 Diagnostic Laboratories
• 8.7 AI & Health Tech Startups

9 Global AI Tumor Evolution Maps Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Azra AI
• 11.2 Siemens Healthineers AG
• 11.3 GE HealthCare
• 11.4 NVIDIA Corporation
• 11.5 Median Technologies
• 11.6 PathAI
• 11.7 Paige
• 11.8 AstraZeneca
• 11.9 CancerIQ
• 11.10 X-ZELL
• 11.11 MNM Bioscience
• 11.12 Biotome
• 11.13 Immunai
• 11.14 OncoHost
• 11.15 Tempus
• 11.16 1Cell.Ai